Sotorasib vs Pembrolizumab for Non-Small Cell Lung Cancer
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Age
- 18 – 100
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 750 (estimated)
- Sponsor
- Amgen · Industry
This trial is looking for people with advanced non-small cell lung cancer who have a specific gene mutation. Participants will receive one of two treatment combinations and will be monitored for their cancer's progress.
You may be able to join if
- I have advanced stage IV or IIIB/C non-small cell lung cancer.
- I have a KRAS G12C mutation.
- I have not received any prior treatment for my cancer.
- I have an ECOG score of 1 or lower.
You may not be able to join if
- I have a different type of lung cancer, like small-cell or large-cell.
- I have brain metastases that are causing symptoms.
- I have gastrointestinal issues that prevent me from taking pills.
- I had a heart attack in the last 6 months.
- I have unstable heart conditions like arrhythmias or angina.
- I have previously been treated with a KRAS G12C inhibitor.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Loading trial locations…